COHANCE444.00

Cohance Lifesciences Ltd.

· Pharma & Health
₹ CrorePeersDIVISLABSYNGENEASTERDMLALPATHLABNATCOPHARMWOCKPHARMANEULANDLABNHMcap ₹16,987 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)317.39273.05290.92290.92
Receivable Days (DSO)46.4086.69109.57109.57
Payable Days (DPO)58.15131.49147.25120.21
Cash Conversion Cycle (days)305.64228.25253.24280.28
Working Capital Turnover0.912.451.972.34
Asset Turnover0.470.400.400.40
Cash Conversion (CFO/Net Income)1.191.092.452.45
CFO/EBITDA0.880.770.860.86
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.